Alan H. Bryce, MD, presented “Putting Germline Testing into Context: A Primer and Current Knowledge” during the 34th International Prostate Cancer Update on February 12, 2024, in Vail, Colorado.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Bryce, Alan H. “Putting Germline Testing into Context: A Primer and Current Knowledge.” February 2024. Accessed Oct 2024. https://grandroundsinurology.com/putting-germline-testing-into-context-a-primer-and-current-knowledge-2/
Putting Germline Testing into Context: A Primer and Current Knowledge – Summary
Alan H. Bryce, MD, explores the critical role of germline testing in prostate cancer, providing a primer on its current applications. He emphasizes identifying these genetic markers for patient management and familial risk assessment.
The 9-minute presentation considers the most relevant genes associated with prostate cancer risk, including BRCA1, BRCA2, and ATM. Dr. Bryce also highlights data problems with germline variants, questioning the representation of diverse racial and ethnic groups in clinical trials.
About The 34th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The 34th iteration of the meeting occurred February 11-14, 2024 in Vail, Colorado. To view more educational presentations from IPCU 34, visit our collection page.
ABOUT THE AUTHOR
Alan H. Bryce, MD, is a medical oncologist and chief clinical officer at City of Hope in Phoenix, Arizona. Dr. Bryce holds an appointment as a professor with the Department of Medical Oncology & Therapeutics Research, with City of Hope, as well as an appointment as a professor of Molecular Medicine at Translational Genomics Research Institute (TGen), which is also part of City of Hope.
Prior to joining City of Hope, Dr. Bryce spent 12 years at the Mayo Clinic in Phoenix, where he served as chair of the Division of Hematology and Medical Oncology, as well as Director of the Mayo Clinic Arizona Comprehensive Cancer Center. Dr. Bryce received his medical degree from the Chicago Medical School, and then completed an internal medicine residency and a hematology and oncology fellowship at the Mayo Clinic in Rochester, Minnesota. During his time at Mayo, Dr. Bryce served as an international co-principal investigator on multiple clinical trials for prostate cancer, with his research focused on cancer genetics, novel therapies and immunotherapeutic approaches.
